Market watch: Upcoming market catalysts in Q2 2017,Nature Reviews Drug Discovery

当前位置： X-MOL 学术 › Nat. Rev. Drug. Disc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Market watch: Upcoming market catalysts in Q2 2017
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2017-03-17 , DOI: 10.1038/nrd.2017.47
Eric Ho

Important market catalysts expected in the second quarter of 2017 include regulatory decisions by the FDA on cerliponase alfa (developed by BioMarin) for treatment of CLN2 disease and brigatinib (developed by Takeda) for the treatment of non-small-cell lung cancer (NSCLC), as well as top-line phase

中文翻译：

市场观察：2017年第二季度即将到来的市场催化剂

预计在2017年第二季度出现的重要市场催化剂包括FDA关于治疗CLN2疾病的cerliponase alfa（由BioMarin开发）和用于治疗非小细胞肺癌（NSCLC）的brigatinib（由Takeda开发）的监管决定。，以及顶线阶段

更新日期：2017-04-11

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11